Journal for ImmunoTherapy of Cancer (Oct 2021)
Correction: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany
Abstract
No abstracts available.
Journal for ImmunoTherapy of Cancer (Oct 2021)